Two subtypes of angiotensin II (Ang II) receptors (AT, and AT2) are distinguished by using the respective specific antagonists. In the present study, we report the regulation of cardiac AT, type A (AT,A) receptor mRNA levels and the expression pattern of AT, and AT2 receptors in the growth of the heart and the development and regression of cardiac hypertrophy. The ventricular AT1A mRNA level and the density of Ang II receptors at the neonatal period were significantly increased (3.5-fold and 2.5-fold, respectively) and then downregulated with maturation. The cardiac hypertrophy established in spontaneously hypertensive rats or two-kidney one-clip renovascular hypertensive rats resulted in substantial increases in ventricular ATMA mRNA levels (threefold) and Ang II receptor densities (twofold) as compared with those in respective control rats, whereas the receptor affinity was similar. The proportion of AT, and AT2 subtypes in the specific Ang II binding in ventricular membranes prepared from normal adult rats was nearly equal. This proportion did not change significantly in the development of myocardial hypertrophy.
T he hypertrophic action of angiotensin II (Ang II) could be mediated by circulating or locally produced hormone.' Evidence demonstrating the presence of an endogenous renin-angiotensin system in the heart includes the demonstration of mRNAs for angiotensinogen and renin,2 angiotensin I (Ang I) converting enzyme,3 and Ang II receptors4 and the detection of Ang I and II radioimmunoreactivities. 5 Upregulation of left ventricular angiotensinogen6 and Ang I converting enzyme mRNAs3 has been described in association with pressure-overload cardiac hypertrophy, suggesting that a cardiac renin-angiotensin system may be activated in cardiac hypertrophy.
Recently, two benzylimidazole derivatives have been used to distinguish Ang II receptor subtypes in several tissues. DuP 753 and TCV-1167 inhibit the Ang II type 1 (AT1) receptor, which is the predominant subtype in the adrenal cortex,8 vasculature,8 kidney,9 and liver,10 whereas PD123319 and CGP42112A inhibit the Ang II type 2 (AT2) receptor, which is present in the adrenal medulla" or brain. 12 The previous study has reported that both AT, and AT2 subtypes are equally distributed over the myocardium." Ang II is one of a growing number of peptide hormones that have been implicated in the regulation of cellular growth'4 and cardiocyte hypertrophy. 15 Beinlich et al16 have demonstrated that Ang II is required for growth of the newborn pig heart by the use of the AT, receptor antagonist.'6 Although this accumulated evidence suggests an activated local renin-angiotensin system in the hypertrophied heart, little is known in terms of the expression pattern of rat cardiac AT, and AT2 receptors, partly because of the paucity of expression in the rat heart. The successful cloning of rat,4'7'8 bovine,19 human,20 and mouse2' AT, receptors has made it possible to study the mechanism of gene expression in the heart at the molecular level. Unexpectedly, rat and mouse hearts have two AT, receptor subtypes, whereas human and bovine hearts seem to have only one subtype. These two AT, receptor subtypes in the rat have high homologous sequences and similar binding and functional characteristics.1718 The AT, receptor that is predominantly expressed in the kidney is termed AT1A and that which is predominantly expressed in the adrenal gland is termed AT1B. '8 The purpose of the present study was to investigate the regulation of cardiac AT1A receptor mRNA levels and the expression pattern of AT, and AT2 receptors in the growth of the heart as well as the development and regression of cardiac hypertrophy. First-strand cDNA was synthesized from total RNA isolated by guanidium isothiocyanate-cesium chloride centrifugation22 with a Gene Amp RNA polymerase chain reaction (PCR) kit from Perkin-Elmer Cetus Instruments, Norwalk, Conn, with random hexamers (2.5 gtmol/L) as primers. 23 The resultant single-strand cDNA was assayed for levels of specific cDNA by quantitative PCR. The following PCR oligonucleotide primers (0.5 ,umol/L) were chosen to amplify the ATlA cDNA4: sense from the 5' noncoding region (5'-GAGTCCTGTTCCACCCGAT-CACCGATCAC) and antisense from the coding region (5 '-GGATGACGCCCAGCTGAATCAGCACATCC).
To obtain deletion-mutated cRNA (A\ATIA), the 1046-bp PCR product was blunt-ended to attach phosphorylated HindlII linkers (New England Biolabs, Beverly, Mass) and subcloned into the Hindlll site of pBluescript II KS(-) (Stratagene Inc, La Jolla, Calif), which was designated pKS. The plasmid was cut by Msc I and self-ligated in order to contain the insert that lacked Msc I-Msc I (288 bp). The deletion-mutated cRNAs were synthesized by T3 RNA polymerase (Takara Shuzo, Kyoto, Japan) after being linearized with BamHI. Total RNA (1 ,tg) and the deletion-mutated cRNA (10 pg) were simultaneously mixed and assayed by the reverse transcription (RT)-PCR method. Denaturing, annealing, and polymerase reactions were performed 30 times at 94°C for 45 seconds, 60°C for 1 minute, and 72°C for 1 minute, respectively. The sizes of RT-PCR products for ATlA mRNA and AAT1A RNA were 1046 and 758 bp, respectively. Specificity of gene amplification was confirmed by correspondence of the size of PCR products to that predicted from the cDNA sequence and by the restriction digestion pattern. As an internal control for input RNA, the rat a-tubulin probe was used for Northern blot analysis, because it has been reported that rat a-tubulin mRNA levels in rat ventricles are unaffected in response to developmental or hypertrophic changes.24 RNA samples were run on 3% formamide and 1% agarose gels in MOPS buffer (20 mmol/L MOPS and 1 mmol/L EDTA, pH 7.4). The RNA was transferred to nylon filters in 10 x standard saline citrate (1 x standard saline citrate contains 0.15 mol/L NaCI and 1.5 mmol/L sodium citrate, pH 7.0). The filters were baked at 80°C for 2 hours and prehybridized and hybridized to the 5'-end-labeled rat a-tubulin (Oncogene Science, Inc, Manhasset, NY) with [y-32P]ATP using T4 polynucleotide kinase under high stringency. 22, 25 The autoradiographic signals were measured by a scanning densitometer.
To quantify the ATlA mRNAs, a trace amount (5 ,uCi) of [32P]dCTP was included in the PCR reaction mixture. The bands of interest were excised from the agarose gel and analyzed in a scintillation counter to measure 32p incorporation and thus the quantity of the PCR product. To control for the efficiency of PCR amplification against tube-to-tube variation and the variability in the amount of input cDNA, ATIA signals were normalized to both deletion-mutated cRNA signals (for PCR efficiency) and rat a-tubulin signals (as internal control) measured by the scanning densitome- Approximately 15 ,ug of protein from the membrane fraction was preincubated in 0.1 mL of the standard medium containing 50 mmol/L imidazole-HCI (pH 7.0), 100 mmol/L NaCl, 16 mmol/IL KCl, 4 mmol/L MgCl2, 1 mmol/L EDTA, and 100 ,g/mL saponin with or without 5 mmol/L ouabain at 37°C for 5 minutes. The reaction was initiated by the addition of 2 mmol/L ATP. The incubation continued for 10 minutes, and the reaction 35% trichloroacetate. The inorganic phosphate (Pi) released in the incubation medium was immediately measured according to the modification of the method of Parvin and Smith.28 The NaX,K+-ATPase activity corresponds to the difference between Pi released in the absence and presence of ouabain into the incubation medium. Cathepsin D activity was determined spectrophotometrically using the method of Anson.29 Reagents and Statistical Methods All reagents were purchased from Sigma Chemical Co, St Louis, Mo, unless otherwise indicated below. Results are expressed as mean+SEM. Analysis of variance and the Newman-Keuls test were used for multigroup comparisons. Values of P<.05 were considered statistically significant.
Results
Developmental Changes in Ventricular ATM mRNA Levels We have used a method for quantification of mRNA levels based on randomly primed RT-PCR as previously described,23 because of the low levels of ATlA mRNA accumulations in the rat heart. To optimize the quantitative RT-PCR, the range of concentrations of sample RNA and internal control cRNA as well as the number of amplification cycles were chosen within the exponential phase (Fig 1, A) , where the quantity of amplified product would be directly proportional to the quantity of starting target sequence. 23 The linear relation in the ratio of sample RNA to internal control cRNA was maintained throughout the range we observed (Fig 1,  B) . To further prove the validity of this method, we have two kinds of RNA samples: one (sample A) is the total RNA isolated from adult rat ventricles, and the other (sample B) is composed of 50% Cos-7 cell total RNA that has no detectable ATlA signal as assessed by our RT-PCR assay and 50% adult rat ventricle total RNA (same as that used in sample A). One microgram of sample A or sample B combined with 2.5, 5, 10, 20, or 50 pg of the deletion-mutated cRNA (AAT1A) was reversetranscribed, and the resultant cDNA mixtures were amplified by PCR. The ratios of radioactivities of ATlA signals to those of AATLA signals were plotted against the amount of the /AATlA combined with total RNA samples. The ratio of slope obtained from sample A to that from sample B is 1.9, which agrees well with the expected value of 2.0 (Fig 1, C) . This indicates that twofold differences in the RNA concentrations can be discernible by our RT-PCR assay and that the concentration of the deletion-mutated cRNA in this range (2.5 to 50 pg) is optimized for the assay.
The previous study has shown that AT, mRNA levels are developmentally regulated in a tissue-specific manner; the steady-state level of AT1 mRNA in the neonatal stage is repressed in the liver but augmented in the kidney compared with the level in adult rats. 17 Our present study demonstrates that ATLA mRNA levels in the heart are also regulated developmentally. As shown in Fig 2, A, the time course of this experiment, the autoradiographic a-tubulin signals used as an internal control for cDNA input were consistently unchanged (Fig 2, A) . To characterize two subtypes of Ang II receptors in ventricular membranes of adult (12-week-old) rats, competition binding experiments were carried out by using their respective antagonists (Fig 4, B) . In the presence of TCV-116 (10 gmol/L), ie, with the putative AT2 left unblocked, the remaining binding sites have a high affinity for PD123319 (IC5,^6±0.2 nmol/L). In the presence of PD123319 (10 gmol/L), with the putative AT1 unmasked, TCV-116 has a relatively high affinity (IC50, 18±0.3 nmol/L). The two receptor populations have an almost identicat high affinity for Ang II (1.5±0.2 and 1.2±0.2 nmol/L in the presence of TCV-116 and PD123319, respectively; see Fig 4, B) . Therefore, from inhibition experiments with these antagonists, the proportion of the receptor subtypes can be estimated. By use of TCV-116, 49±2% (n-4) of the Ang II binding sites in 12-week-old rat ventricles were not blocked and can therefore be classified as AT2 receptors, whereas 51±2% (n=4) were sensitive to this compound and can be assigned to the AT1 receptor (Fig  2, B) . The similar proportion of receptor subtypes was obtained in the reverse experiments using PD123319 as a competitor. These receptor studies were used to examine the developmental and hypertrophic changes in Ang II receptor subtype expression.
As shown in Fig 2, cles, whereas Kd values did not significantly change in the development (0.9±0.1 nmol/L after 1 day, 1.0±0.1 nmol/L after 4 days, 1.0+0.1 nmol/L after 7 days, 1.0±0.1 nmol/L after 4 weeks, 0.9±0.2 nmol/L after 12 weeks, and 0.9±0.1 nmol/L after 17 weeks; n=4 rats at each time point). Inhibition experiments with receptor antagonists revealed the similar proportion of the receptor subtypes during the development of the heart (Fig 2, B) , suggesting that both AT1 and AT2 expressions are developmentally regulated in a similar manner. expressions in the hypertrophied ventricles of SHR and RHR. The receptor densities were significantly increased in SHR (1.8-fold, P<.01) and 2K1C RHR (twofold, P<.01) as compared with those in their respective control groups, whereas the Kd values were similar between the hypertrophic and normotensive rat ventricles (0.9±0.1 nmol/L for 24-week-old SHR, 1.0±0.2 nmol/L for 24-week-old WKY rats, 1.0±0.2 nmol/L for RHR untreated for 10 weeks after clipping, 0.9±0.2 nmol/L for sham-operated control rats, and 1.0±0.2 nmol/L for RHR treated with nephrectomy; n=4 rats in each experimental group). Study of Ang II receptor subtypes has demonstrated that nearly equal proportions of AT1 and AT2 receptors are expressed in hypertrophied and normal ventricles, resulting in a significant increase (P<.05) in both receptor numbers in response to hypertrophic change (Fig 3, C and D) . Discussion The hypertrophic action of Ang II could be mediated by circulating or locally produced hormone. Although the constituents for an intracardiac renin-angiotensin system, including the mRNAs for angiotensinogen,2,6 renin,2 Ang I converting enzyme,3 and Ang II receptors,4 are present in the heart, the physiologically relevant autocrine or paracrine functions in the heart have not been established yet. In the present study, we showed for the first time that ATlA mRNA accumulations are induced more than threefold in hypertrophied ventricles relative to control ventricles. This induction was seen consistently in SHR as well as 2K1C RHR, and the regression of hypertrophy with the AT, antagonist normalized the increase at mRNA levels, indicating that these interesting phenomena are a specific and consistent feature of hypertrophied myocardium. In the initial part of the experiment examining the ATlA mRNA changes in the 2K1C RHR mRNA levels are increased in 16-week-old SHR ventricles as compared with 16-week-old WKY ventricles, whereas ATlA mRNA levels were almost the same between the two strains at this age. Although the proportion of ATlA mRNA and AT,0 mRNA levels was not determined in the present study, the AT1A mRNA levels in 17-week-old SHR were similar to those in the 17-week-old WKY rats and thereafter significantly increased in the older SHR compared with age-matched WKY rats (Fig 3, A) . Since the ventricular hypertrophy estimated by left ventricle/body weight ratio has not developed by 17 weeks in SHR (Table), The results of our binding assay demonstrate that the densities of high-affinity Ang II receptors are increased in the hypertrophied ventricle. Analysis of binding data using the inhibitors TCV-116 and PD123319 suggested that two classes (AT, and AT2) of Ang II receptors with high affinity for the ligands are present in the ventricle in a nearly equal proportion, consistent with previous observations in the rabbit27 and rat."' It has been shown that the AT2 receptor is highly expressed in the mesenchymal tissue of the developing rat fetus and rapidly disappears after birth33 and that during embryonic and 
